Literature DB >> 16006595

Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells.

Zhihua Xie1, Rashmi G Bhushan, David J Daniels, Philip S Portoghese.   

Abstract

KDN21 is a bivalent ligand that contains delta and kappa opioid antagonist pharmacophores linked through a 21-atom spacer. It has been reported that KDN21 bridges delta and kappa receptors that are organized as heterodimers. We have shown previously that when using [(3)H]diprenorphine as radioligand, KDN21 displayed greatly enhanced affinity in this series for coexpressed delta and kappa opioid receptors (CDK). The present study used in vitro expression systems to investigate interactions of members of the KDN series with delta-kappa heterodimers through competition binding using selective ligands and the mitogen-activated protein kinase (MAPK) assay. In this regard, the use of the selective radioligands [(3)H]naltrindole and [(3)H]norbinaltorphimine (nor-BNI) in competition binding studies revealed that KDN21 has much higher affinity than other KDN members for CDK and bound to CDK more selectively relative to mixed delta and kappa opioid receptors or singly expressed delta and kappa opioid receptors. Other experiments revealed that the binding of naltrindole to delta opioid receptors could increase the binding of nor-BNI to kappa opioid receptors and vice versa, suggesting reciprocal allosteric modulation of receptors in the heterodimer. Regarding the selectivity of KDN21 for phenotypic delta and kappa opioid receptors, we investigated the effect of KDN21 on the activation of MAPKs [extracellular signal-regulated kinases 1 and 2 (ERK1/2)] by delta- or kappa-selective agonists. KDN21 inhibited the activation of ERK1/2 by [D-Pen(2),D-Pen(5)]-enkephalin (delta(1)) and bremazocine (kappa(2)) but had no effect on the activation by deltorphin II (delta(2)) and (+)-(5alpha,7alpha,8beta)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]benzeneacetamide (U69593, kappa(1)). 7-Benzylidenenaltrexone (delta(1)) and bremazocine (kappa(2)) significantly reduced the binding of KDN21 to CDK, whereas naltriben (delta(2)) and U69593 produced no such change. Taken together, these data support the idea that the organization of delta and kappa receptors as heterodimers gives rise to delta(1) and kappa(2) phenotypes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16006595     DOI: 10.1124/mol.105.012070

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  32 in total

1.  Allosteric interactions between δ and κ opioid receptors in peripheral sensory neurons.

Authors:  Kelly A Berg; Matthew P Rowan; Achla Gupta; Teresa A Sanchez; Michelle Silva; Ivone Gomes; Blaine A McGuire; Philip S Portoghese; Kenneth M Hargreaves; Lakshmi A Devi; William P Clarke
Journal:  Mol Pharmacol       Date:  2011-11-09       Impact factor: 4.436

2.  Consequences of opioid receptor mutation on actions of univalent and bivalent kappa and delta ligands.

Authors:  Michael A Ansonoff; Philip S Portoghese; John E Pintar
Journal:  Psychopharmacology (Berl)       Date:  2010-03-24       Impact factor: 4.530

3.  Opioid and cannabinoid receptors: friends with benefits or just close friends?

Authors:  MacDonald J Christie
Journal:  Br J Pharmacol       Date:  2006-05-08       Impact factor: 8.739

Review 4.  A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization.

Authors:  G Milligan
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

Review 5.  G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function.

Authors:  Graeme Milligan
Journal:  Br J Pharmacol       Date:  2009-03-20       Impact factor: 8.739

6.  Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series.

Authors:  David J Daniels; Natalie R Lenard; Chris L Etienne; Ping-Yee Law; Sandra C Roerig; Philip S Portoghese
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

7.  Implication of delta opioid receptor subtype 2 but not delta opioid receptor subtype 1 in the development of morphine analgesic tolerance in a rat model of chronic inflammatory pain.

Authors:  H Beaudry; L Gendron; J A Morón
Journal:  Eur J Neurosci       Date:  2015-01-09       Impact factor: 3.386

8.  MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats.

Authors:  Diana V Atigari; Rajendra Uprety; Gavril W Pasternak; Susruta Majumdar; Bronwyn M Kivell
Journal:  Neuropharmacology       Date:  2019-02-13       Impact factor: 5.250

Review 9.  Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse.

Authors:  Ivone Gomes; Wakako Fujita; Moraje V Chandrakala; Lakshmi A Devi
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

10.  Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine.

Authors:  Toni S Shippenberg; Vladimir I Chefer; Alexis C Thompson
Journal:  Biol Psychiatry       Date:  2008-10-31       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.